Antiva wants to help treat cervical cancer. Most male investors aren't interested.
A young pharmaceutical startup wants to develop a groundbreaking new treatment for a relatively common cancer. Yet it struggles to find funding.
That's because the startup in question is Antiva Biosciences, and the cancer it aims to treat is cervical cancer. Stat reported Thursday on the company's struggles to attract investment, as well as its constant fight to receive buy-in from male doctors, quoting Antiva's top executives discussing frankly their perceptions of the problem: "It's very safe to say that we got more traction in [venture capital] firms where there was a woman partner who was in a decision-making role," Antiva CEO Gail Maderis told Stat.
Antiva's proposal is to replace the most common treatment prescribed for women who develop the precancerous cervical lesions that result from being infected with HPV, which is surgery. The operation removes the lesions by "essentially cutting off the tip of the cervix," Stat reports. The surgery has proven effective in eradicating the problem cells, but "women of childbearing age who undergo the surgery may later have difficulty conceiving, recurrent miscarriages, and preterm delivery," Stat explains.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Antiva says about 500,000 women undergo this procedure every year. Instead of surgery, the company is proposing a topical treatment that patients can administer themselves. But the reception has been lukewarm: Maderis told Stat of how one prospective male investor who appeared unenthused during Maderis' pitch. But after their meeting, he called Maderis to explain how his wife had pressed him to investigate the deal further after he'd told her about the company's mission.
One man, David Kabakoff, did invest in Antiva through his firm. His team has been calling gynecologists to glean their reactions to the topical treatment. "The trend was unmistakable," Stat wrote: "Male physicians tended to express skepticism ... Female physicians tended to say new treatment options are badly needed." Read more about Antiva at Stat.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Kimberly Alters is the news editor at TheWeek.com. She is a graduate of the Medill School of Journalism at Northwestern University.
-
'The House under GOP rule has become a hostile workplace'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
The Shohei Ohtani gambling scandal is about more than bad bets
In The Spotlight The firestorm surrounding one of baseball's biggest stars threatens to upend a generational legacy and professional sports at large
By Rafi Schwartz, The Week US Published
-
Feds raid Diddy homes in alleged sex trafficking case
Speed Read Homeland Security raided the properties of hip hop mogul Sean "Diddy" Combs
By Peter Weber, The Week US Published
-
Reddit IPO values social media site at $6.4 billion
Speed Read The company makes its public debut on the New York Stock Exchange
By Peter Weber, The Week US Published
-
Housing costs: the root of US economic malaise?
speed read Many voters are troubled by the housing affordability crisis
By Peter Weber, The Week US Published
-
Feds cap credit card late fees at $8
speed read The Consumer Financial Protection Bureau finalized a rule to save households an estimated $10 billion a year
By Peter Weber, The Week US Published
-
Immigration helped the US economy outpace peers
speed read The U.S. economy grew at an annualized rate of 3.2% last quarter
By Peter Weber, The Week US Published
-
4-day workweek gets boost from UK study
Speed Read Following a six-month trial, the majority of participating British companies are still using the truncated schedule
By Peter Weber, The Week US Published
-
US sues to block Kroger-Albertsons merger
Speed Read The Federal Trade Commission sued to block the $24.6 billion merger between the grocery giants
By Peter Weber, The Week US Published
-
Nvidia sees historic stock rise on AI chips success
Speed Read U.S. chipmaker Nvidia achieved the biggest one-day increase in value of any company in history
By Peter Weber, The Week US Published
-
New York may seize Trump's assets for $450M penalty
Speed Read The former president likely owes $600 million from two civil judgments in New York
By Peter Weber, The Week US Published